Ischemic Stroke: New Neuron Recovery Approach with Mesenchymal and Neural Stem Cells

A. Chouw, R. Triana, Nurrani Mustika Dewi, S. Darmayanti, Miftakh Nur Rahman, Ardian Susanto, Bayu Winata Putera, C. R. Sartika
{"title":"Ischemic Stroke: New Neuron Recovery Approach with Mesenchymal and Neural Stem Cells","authors":"A. Chouw, R. Triana, Nurrani Mustika Dewi, S. Darmayanti, Miftakh Nur Rahman, Ardian Susanto, Bayu Winata Putera, C. R. Sartika","doi":"10.21705/MCBS.V2I2.28","DOIUrl":null,"url":null,"abstract":"Stroke is a leading cause of death and long-term disability. This due to the ischemic event that cause by embolism of blockage blood flow. Thrombolytic agent plasminogen activator (tPA) is the only treatment approved by FDA. However, the used of tPA is limited to the short time window period. Neural stem cells (NSCs) show the potential to repair neuronal damage naturally after stroke. However, isolating NSCs is a challenging process due to the limitations of the method and its invasiveness. Some studies that had used mesenchymal stem cell (MSCs) as the main source of stem cell for therapy show that MSCs have the potency to differentiate into NSCs. in vitro, a differentiation process from MSC to NSC has been developed by combining the supplement or growth factor needed in the culture media.Keywords: stem cells, neuron stem cell, mesenchymal stem cell, stroke, trans-differentiation","PeriodicalId":53387,"journal":{"name":"MCBS Molecular and Cellular Biomedical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MCBS Molecular and Cellular Biomedical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21705/MCBS.V2I2.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Stroke is a leading cause of death and long-term disability. This due to the ischemic event that cause by embolism of blockage blood flow. Thrombolytic agent plasminogen activator (tPA) is the only treatment approved by FDA. However, the used of tPA is limited to the short time window period. Neural stem cells (NSCs) show the potential to repair neuronal damage naturally after stroke. However, isolating NSCs is a challenging process due to the limitations of the method and its invasiveness. Some studies that had used mesenchymal stem cell (MSCs) as the main source of stem cell for therapy show that MSCs have the potency to differentiate into NSCs. in vitro, a differentiation process from MSC to NSC has been developed by combining the supplement or growth factor needed in the culture media.Keywords: stem cells, neuron stem cell, mesenchymal stem cell, stroke, trans-differentiation
缺血性脑卒中:间充质干细胞和神经干细胞恢复神经元的新途径
中风是导致死亡和长期残疾的主要原因。这是由于血栓阻塞血流所引起的缺血事件。溶栓剂纤溶酶原激活剂(tPA)是唯一获得FDA批准的药物。然而,tPA的使用仅限于较短的时间窗口期。神经干细胞(NSCs)显示出在中风后自然修复神经元损伤的潜力。然而,由于方法的局限性及其侵袭性,分离NSCs是一个具有挑战性的过程。一些利用间充质干细胞(mesenchymal stem cell, MSCs)作为主要干细胞来源进行治疗的研究表明,MSCs具有向NSCs分化的潜能。在体外,通过结合培养基中所需的补充或生长因子,形成了从MSC到NSC的分化过程。关键词:干细胞,神经元干细胞,间充质干细胞,中风,转分化
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信